Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy
Open Access
- 15 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11), e49279
- https://doi.org/10.1371/journal.pone.0049279
Abstract
To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients. To analyze the impact of metformin on glutaminase activity and ammonia production in vitro. Eighty-two cirrhotic patients with type 2 diabetes were included. Forty-one patients were classified as insulin sensitizers experienced (metformin) and 41 as controls (cirrhotic patients with type 2 diabetes mellitus without metformin treatment). Baseline analysis included: insulin, glucose, glucagon, leptin, adiponectin, TNFr2, AST, ALT. HOMA-IR was calculated. Baseline HE risk was calculated according to minimal hepatic encephalopathy, oral glutamine challenge and mutations in glutaminase gene. We performed an experimental study in vitro including an enzymatic activity assay where glutaminase inhibition was measured according to different metformin concentrations. In Caco2 cells, glutaminase activity inhibition was evaluated by ammonia production at 24, 48 and 72 hours after metformina treatment. Hepatic encephalopathy was diagnosed during follow-up in 23.2% (19/82): 4.9% (2/41) in patients receiving metformin and 41.5% (17/41) in patients without metformin treatment (logRank 9.81; p = 0.002). In multivariate analysis, metformin use [H.R.11.4 (95% CI: 1.2–108.8); p = 0.034], age at diagnosis [H.R.1.12 (95% CI: 1.04–1.2); p = 0.002], female sex [H.R.10.4 (95% CI: 1.5–71.6); p = 0.017] and HE risk [H.R.21.3 (95% CI: 2.8–163.4); p = 0.003] were found independently associated with hepatic encephalopathy. In the enzymatic assay, glutaminase activity inhibition reached 68% with metformin 100 mM. In Caco2 cells, metformin (20 mM) decreased glutaminase activity up to 24% at 72 hours post-treatment (pin vitro. Therefore, metformin use seems to be protective against hepatic encephalopathy in diabetic cirrhotic patients.Keywords
This publication has 21 references indexed in Scilit:
- The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trialJournal of Pediatric Endocrinology and Metabolism, 2012
- Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosisLiver International, 2011
- Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expressionChemico-Biological Interactions, 2011
- The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitisTherapeutic Advances in Gastroenterology, 2011
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver diseaseLiver International, 2010
- Pharmacotherapy of hepatic encephalopathy in cirrhosisExpert Opinion on Pharmacotherapy, 2010
- Predictors of minimal hepatic encephalopathy in patients with cirrhosisSaudi Journal of Gastroenterology, 2010
- Association Between Small Intestinal Bacterial Overgrowth and Peripheral Bacterial DNA in Cirrhotic PatientsDigestive Diseases and Sciences, 2009
- Segregation of two glutaminase isoforms in islets of LangerhansBiochemical Journal, 2004
- Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathyThe American Journal of Gastroenterology, 2001